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Abstract
Objective: We describe an external quality assurance (EQA) study designed to assess the efficiency and accurateness of
molecular and serological methods used by expert laboratories performing YF diagnosis.
Study Design: For molecular diagnosis evaluation, a panel was prepared of 14 human plasma samples containing specific
RNA of different YFV strains (YFV-17D, YFV South American strain [Brazil], YFV IvoryC1999 strain), and specificity samples
containing other flaviviruses and negative controls. For the serological panel, 13 human plasma samples with anti-YFV-
specific antibodies against different strains of YFV (YFV-17D strain, YFV IvoryC1999 strain, and YFV Brazilian strain), as well as
specificity and negative controls, were included.
Results: Thirty-six laboratories from Europe, the Americas, Middle East, and Africa participated in these EQA activities. Only
16% of the analyses reported met all evaluation criteria with optimal performance. Serial dilutions of YFV-17D showed that
in general the methodologies reported provided a suitable sensitivity. Failures were mainly due to the inability to detect
wild-type strains or the presence of false positives. Performance in the serological diagnosis varied, mainly depending on
the methodology used. Anti-YFV IgM detection was not performed in 16% of the reports using IIF or ELISA techniques,
although it is preferable for the diagnosis of YFV acute infections. A good sensitivity profile was achieved in general;
however, in the detection of IgM antibodies a lack of sensitivity of anti-YFV antibodies against the vaccine strain 17D was
observed, and of the anti-YFV IgG antibodies against a West African strain. Neutralization assays showed a very good
performance; however, the unexpected presence of false positives underlined the need of improving the running protocols.
Conclusion: This EQA provides information on each laboratory’s efficacy of RT-PCR and serological YFV diagnosis
techniques. The results indicate the need for improving serological and molecular diagnosis techniques and provide a
follow-up of the diagnostic profiles.
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Introduction
Yellow fever (YF) is a viral disease which is symptomatic in
about 5–20% of infected people. In its mildest form YF is
characterized by non-specific fever and headache, while the severe
form of the disease is characterized by high fever, jaundice,
bleeding, and eventually shock and multiple organ failure. Among
those who develop severe disease 20–50% may die. To date, there
are no antivirals for specific treatment of the infection, and YF
vaccination of the population at risk is the best approach to
prevent and control the disease [1,2].
Yellow fever virus (YFV) is transmitted to humans by bites of
infected mosquitoes. In the jungle setting, mosquitoes and
monkeys maintain the virus via an enzootic cycle. The virus can
also be transmitted vertically from female mosquitoes to eggs as a
maintenance mechanism from one year to the next. A second
transmission cycle, the urban cycle, involves humans and the
mosquito species Aedes (Stegomyia) aegypti. An intermediary cycle is
maintained in humid and semi-humid African savannas with viral
transmission to humans and to non-human primates through
different Aedes sp. Mosquito control is not possible in areas of
sylvatic transmission, thus eradication of YF is not a plausible
option [3].
YF remains an important public health problem for people in
endemic regions in Africa and South America and is considered an
emerging disease, with a dramatic upsurge in the number of cases
in recent years [4]. YF cases occur every year in Africa. For
example, during 2011 cases from Senegal, Sierra Leone, Uganda,
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Organization (WHO) (http://www.who.int). In the Americas,
the circulation of jungle YF has experienced an unexpected
increase since 2008, affecting Argentina, Brazil, Colombia,
Paraguay, and Venezuela on the continent and Trinidad and
Tobago in the Caribbean. Remarkably, a number cases of urban
transmission have been reported in Bolivia [5], and Paraguay has
dealt with an outbreak of apparently urban YF [6]. The real
incidence of YFV infections worldwide is unknown due to the non-
specific nature of the symptoms leading to misdiagnoses, together
with insufficient reporting and ground-surveillance, and it is
estimated to be over 200,000 cases per year [1].
The clinical diagnosis of YF and the identification of YFV
vaccine-associated adverse events (YFVAE) are particularly
difficult because of similar symptoms of a wide range of diseases
(e.g. dengue, leptospirosis, viral hepatitis, malaria, hemorrhagic
viral diseases), therefore laboratory confirmation is essential. As
criteria for laboratory YF diagnosis, WHO recommends the
detection of YFV-specific IgM or a fourfold or greater rise in
serum IgG levels in the absence of recent YF vaccination and a
negative diagnosis for other flaviviruses. Isolation of YFV, positive
post-mortem liver histopathology, detection of YFV antigen in
tissues by immunohistochemistry, or detection of YFV genome in
blood or organs by RT-PCR also confirm the presence of YFV
infection [7]. Recently, we have reported the detection of YFV-
17D genome in the urine of healthy YF vaccinees and vaccinees
with serious post- vaccination adverse events, which seems very
promising for the investigation in outbreak situations by non-
invasive sampling methods [8].
Molecular methods for the detection of the viral genome offer a
rapid, sensitive, and highly specific alternative for early serological
diagnosis during the viraemic phase of infection or in post-mortem
tissues. After the viraemic phase the use of serological methods
represents a good option to confirm the infection, but generally
two samples are required to be taken at least two weeks apart.
Serological diagnosis commonly includes the use of haemagglu-
tination, ELISA, indirect immunofluorescence (IIF) and seroneu-
tralization assays, but flavivirus serological cross-reactions consti-
tute a major obstacle in achieving confirmed diagnoses or reliable
serosurveys in endemic areas where other flaviviruses circulate
(e.g. dengue, Zika, St. Louis encephalitis, or West Nile viruses).
Seroneutralization is considered as the most specific serological
technique. However, the assays are laborious and time consuming
and are only available in expert laboratories. But the availability of
commercial assays for the serological diagnosis of YF has increased
the implementation of such techniques. Commercial assays are, in
general, thoroughly standardized and offer good standards of
sensitivity, specificity, and reproducibility in diagnostic laborato-
ries in order to receive the authorisation for in vitro diagnostics.
The performance of the different techniques applied in YF
diagnosis may vary between laboratories, and so far no external
quality assessment (EQA) studies addressing their accomplishment
have been performed. This international EQA is an important tool
to evaluate the performance of protocols currently in use in
diagnostic laboratories and to highlight weaknesses in their
methodologies and operating procedures.
Materials and Methods
Participants
Institutions involved in laboratory diagnostics of YFV infection
were invited to participate in this study. Invitees consisted of
members of the European Network of ‘‘Imported’’ Viral Diseases
(ENIVD), national/regional YFV reference laboratories, and
diagnostic laboratories contacted through the Pan American
Health Organization (PAHO) or the African Network of
Laboratories for polioviruses and hemorrhagic fevers diagnosis.
The study was announced as an EQA study on YFV molecular
and serological diagnostic methods proficiency, which included
certifying and publishing the results in a comparative and
anonymous manner.
Thirty-six laboratories from Europe (n=28), the Americas
(n=7), Middle East Asia (n=1), and Africa (n=1) participated in
these EQA activities, and reports including 32 and 31 data sets of
results were returned for the molecular (28 laboratories) and
serological (28 laboratories) diagnosis EQAs, respectively.
Twenty laboratories participated both in the molecular diag-
nostics EQA and the serological diagnostics EQA from Europe
(n=15), the Americas (n=4), and Africa (n=1): IRBA-IMTSSA,
Marseille, France; Bernhard-Nocht-Institut, Hamburg, Germany;
Institut fu ¨r Mikrobiologie der Bundeswehr, Munich, Germany;
Aristotle University of Thessaloniki, School of Medicine, Greece;
Istituto Nazionale per le Malattie Infettive ‘‘L. Spallanzani’’,
Rome, Italy; Fondazione IRCCS Policlinico San Mateo, Pavia,
Italy; Norwegian Institute of Public Health, Oslo, Norway;
CEVD/INS, Aguas de Moura, Portugal; Institute of Microbiology
and Immunology, University of Ljubljana, Ljubljana, Slovenia;
Instituto de Salud Carlos III, Madrid, Spain; Hospital Clı ´nic i
Provincial de Barcelona, Barcelona, Spain; Spiez Laboratory,
Spiez, Switzerland; University of Geneva, Geneva, Switzerland;
Erasmus Medical Centre, Rotterdam, The Netherlands; Health
Protection Agency, CEPR, Porton Down, Salisbury, United
Kingdom; Centro Nacional de Enfermedades Tropicales, CEN-
ETROP, Santa Cruz, Bolivia; Instituto Nacional de Salud,
Bogota ´, Colombia; Institut Pasteur de la Guyane, Cayenne Cedex,
French Guiana; Laboratorio Central de Salud Pu ´blica, Asuncio ´n,
Paraguay; Special Pathogens Unit, National Institute for Com-
municable Diseases, National Health Laboratory Service, SPU/
NICD-NHLS, Johannesburg, South Africa.
Eight laboratories participated exclusively in the YFV molecular
diagnostics EQA, from Europe (n=7) and the Middle East (n=1):
Institute of Virology, Medical University Vienna, Vienna, Austria;
Slovak Academy of Science, Bratislava, Slovakia; Assistance
Publique-Ho ˆpitaux de Marseilles, Ho ˆpital de la Timone, AP-
HM TIMONE, Marseille, France; Army Medical and Veterinary
Research Center, Rome, Italy; Centre for Biothreat Preparedness,
Helsinki, Finland; Universita ¨tsklinikum Freiburg, Freiburg, Ger-
many; Institut fu ¨r Virologie, Marburg, Germany; National Center
for Zoonotic Viruses, MOH-PHL, Tel-Hashomer, Israel.
Eight laboratories participated exclusively in the serological
diagnosis EQA, from Europe (n=5) and the Americas (n=3);
Instituut voor Tropische Geneeskunde, Antwerp, Belgium; Insti-
tute of Public Health, Ostrava, Czech Republic; Euroimmun AG,
Lu ¨beck, Germany; National Center for Epidemiology, Budapest,
Hungary; Crucell Switzerland AG, Berne, Switzerland; Bio
Manguinhos, Rio de Janeiro, Brazil; Viral Zoonoses National
Microbiology Laboratory, Winnipeg, Manitoba, Canada; Instituto
Nacional de Higiene y Medicina Tropical ‘‘LIP’’, Guayaquil,
Ecuador.
The European Network for the Diagnostics of ‘Imported’ Viral
Diseases -Collaborative Laboratory Response Network (ENIVD-
CLRN) established and coordinated this EQA as in other EQAs
previously performed [9–12].
Specimen preparation
The molecular diagnosis EQA panel consisted of inactivated
YFV preparations generated from Vero E6 cell culture superna-
tants infected with different YFV strains: the vaccine strain (YFV-
Yellow Fever Diagnosis External Quality Assessment
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(IvoryC1999) [13]. Supernatants were inactivated by heating for
1 h at 56uC and by gamma irradiation (25 kilogray [kGy]) to
ensure their non-infectivity. The inactivated supernatant viral load
was estimated after heat inactivation and additionally after gamma
irradiation by an in-house real-time RT-qPCR with a 95%
detection limit in copy number estimated in 6.48 copies/reaction
(rxn) (95% CI: 2.35–235 copies/rxn) (C. Domingo, unpublished
results).
The inactivated material was diluted in serum plasma to
prepare a set of ten positive samples that included five serial 10-
fold dilution series of YFV-17D (3610
6 Genome equivalents
[GE]/sample to 3610
2 GE/sample), two YFV (Brazil) dilutions
(10
4 GE/sample and 10
3 GE/sample), and three YFV (strain
IvoryC1999; GenBank Acc. No.: AY603338) dilutions (2610
4
GE/sample to 69 GE/sample). As specificity controls we prepared
two additional plasma samples, one of them containing West Nile
virus (WNV [New York]), Japanese encephalitis virus (JEV [strain
SA-14-02]), St. Louis encephalitis virus (SLEV [Parton]), and tick-
borne encephalitis virus (TBEV [strain Absettarov]). The second
plasma sample contained the four dengue serotypes (DENV-1
VR344 [strain Thai 1958], DENV-2 VR345 [TH-36 strain],
DENV-3 VR216 [H87 strain], and DENV-4 VR217 [H241
strain]). Two negative control plasma samples were also included
(Table 1).
Sample preparations were tested by an in-house real-time
quantitative RT-PCR to validate the quality of the samples.
For the serological diagnosis, a panel of 13 samples was
prepared by diluting anti-YFV-positive sera from YF vaccinees
and from wild-type YFV infections with fresh frozen plasma
previously confirmed as negative for flaviviruses. After dilution, the
samples were heat inactivated (56uC, 1 h). The proficiency panel
consisted of a set of nine samples which included four serial 2-fold
dilutions of YFV-17D-positive sera (IgM and IgG positive), two
dilutions from a West African wild-type YFV infection serum (IgM
negative, IgG positive), and three dilutions from a positive South
American wild-type YFV infection serum (IgM and IgG positive).
As specificity controls, we included aliquots of two sera containing
IgM and IgG antibodies reactive for other flaviviruses (WNV,
DENV) and two additional negative sera as controls (Table 2).
For both panels, aliquots of 100 ml each were number-coded,
freeze dried for 24 h (Christ, AlphaI-5, Hanau, Germany) and
stored at 4uC until dispatch.
Validation of the panel sets and dispatch
To validate the molecular panel, we tested three different sets of
EQA samples before distribution by the Robert Koch Institute
(RKI), Berlin, Germany. After reconstitution with 100 ml of water,
the samples were extracted using the QIAamp viral RNA minikit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. As mentioned above, we estimated the YFV genome
copies present in these samples by an in-house real-time RT-PCR
(Table 1).
Similarly, two sets of samples for the serological EQA panel
were validated before distribution. After reconstitution with 100 ml
of water, samples were analyzed by IIF for the presence of specific
YFV antibodies using commercially available kits (FK 2665-1010-
G and FK 2665-1010-M, Anti-yellow fever virus IIFT, Euro-
immun, Lu ¨beck, Germany) following the manufacturer’s instruc-
tions. These assays have demonstrated a specificity of 94.7% and
96.7% in the detection of IgG and IgM antibodies in two panels of
patient sera involving 300 and 294 sera each. Similarly, their
sensitivity was determined as 94.7% for IgG and 94.4% for IgM
(stated by manufacturer). A microneutralization assay in Vero E6
cells was also carried out to confirm the presence and specificity of
the antibodies as previously described [14].
The EQA panels were distributed to participants with full
instructions. Samples were shipped at ambient temperature by
post to participating laboratories. We requested participant
laboratories to resuspend the samples in 100 ml of water and to
analyse the material as serum samples for YFV molecular/
serological diagnosis as done routinely. They were asked to report
their results and any problems encountered, as well as to provide
information on the protocol details (RT-PCR method, extraction
procedure, serological methods, sera dilution) using a common
form included in the documentation.
Evaluation of the results
To assure anonymous participation, an individual numerical
identification code was assigned to the results sent by each
laboratory. This number was followed by a letter (a, b) in case
different laboratory results were received based on different
methods.
A scoring system was established for sensitivity and specificity
obtained by each participant laboratory. For the molecular
diagnostics EQA evaluation we assigned two points for correct
results (100%=28), and penalised false-positive results with -
2 points. We considered those methods as non-optimal which
failed to detect one or more strains of YFV, or presented false-
positive results in the negative samples. In those cases when a false-
positive amplification result was obtained by RT-PCR in the
‘‘non-specificity control’’ samples (#3 and #11), which were
however correctly identified by sequencing, the result was
considered correct.
For the serological diagnostics EQA evaluation we also assigned
two points for correct results (100%=26), whereas false-negative/-
positive results were not scored. Equivocal or borderline results
were considered as positive. IgM and IgG results were considered
separately.
The complete panel of results was sent to the participants in an
anonymous manner where they could only identify the results
from their own laboratory.
Statistical Analysis
Data collected were entered into Microsoft Excel (Microsoft
Corp., Bellingham, WA, USA) and analysed using SPSS 14.0 for
Windows (SPSS Inc., Chicago, IL, USA).
Logit analysis was used to evaluate the effect of viral RNA
concentration on the RT-PCR performance by using cumulative
fractions of positive results reported for each test sample of the 10-
fold dilution series of YFV-17D. The result reflects the perfor-
mance of a hypothetical average laboratory.
Results with respect to categorised variables were analysed by
McNemar’s test. T-test and Mann-Whitney tests were used to
estimate the effect of the real-time RT-PCR format on the
performance. P-value,0.05 was considered to indicate statistical
significance.
Results
A total of 36 laboratories participated in this EQA. Among the
participants, 20 laboratories (56%) reported both serological and
molecular results, indicating that they included both approaches in
their diagnostic algorithm. However, 22% (8 out of 36) of the
participants only applied either molecular or serological tech-
niques, respectively.
A total of 32 laboratory results were received for the molecular
diagnosis study (Table 1), including four double sets from
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A total of 31 laboratory results were received for the serological
diagnosis study (Table 2), including three double sets from
laboratories using two methods each (sets 12ab, 14ab, 20ab).
Molecular diagnosis results
A variety of tests were used for screening and identification of
YFV genome by participating laboratories; these included RT-
PCR (n=2, 6% of the laboratory results) [15,16], RT-nested PCR
(n=8, 25%) [15,17,18], hemi-nested RT-PCR (n=2, 6%) [19],
TaqMan (n=19, 60%) [16,20–24], and SYBR Green [23] (n=1,
3%)-based real-time RT-PCR assays (Table 1). As many as ten
published protocols (indicated in Table 1) were used by
participants and only three methods were established ‘‘in house’’
(9.37%). Eight laboratories used the TaqMan RT-PCR developed
by Drosten et al. [20], and six of them reported using the TaqMan
RT-PCR developed by Bae et al. [21], in both cases with varying
performance depending on the reporting laboratory.
Performance varied among the 28 laboratories (Table 1). Five
out of 32 (16%) analyses reported met all criteria with optimal
performance; 13 out of 32 (41%) test results achieved non-optimal
results due to the failure to detect one or more YFV strains (in 12
sets of results wild-type strains were not detected, whereas in one
data set the YF-17D strain was not detected). One laboratory did
not report any positive results. Additionally, 78% (25 out of 32) of
laboratory results reported false positives; 21 laboratory reports
falsely identified YFV in samples containing other flaviviruses (#3
and #11) and four do so in negative samples (Table 1).
Serial dilutions of YFV-17D (samples #2, #9, #12, #4, and
#14) were used in order to test the sensitivity of the different
methods. To estimate the effect of virus concentration on RT-
PCR performance, Logit analysis was carried out using cumulative
RT-PCR-positive results reported for each sample of the 10-fold
YFV-17D dilution series (Figure 1). The data demonstrated that
50% of positive performance could be expected at a concentration
of 2.8610
2 GE/sample (95% confidence interval [CI] 11.7–
1.2610
3 GE/sample). Ninety-five percent performance could be
Figure 1. Logit analysis of laboratory tests with a correct result
(y axis) for YFV-17D related to viral RNA concentration in
positive samples (x axis). Data points represent individual samples
in the panel. Thick line is the regression line calculated on the basis of a
logit model (dose–response curve), and thin lines are 95% confidence
intervals.
doi:10.1371/journal.pone.0036291.g001
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6 GE/sample (95% CI 1.9610
5–2.8610
8
GE/sample).
Comparison of the results obtained for similar concentrations of
different YFV strains (Table 1) also suggests the effect of virus type
on the performance. Thus the results for YFV-17D were
significantly better than those for the IvoryC1999 strain
(McNemar’s test was performed for sample #12 versus sample
#13 and for sample #4 versus sample #1). The performance for
YFV-17D was also significantly higher than that for the Brazilian
strain (McNemar’s test performed for sample #12 versus sample
#10 and for sample #4 versus the sample #5). At the same time
no essential difference in test performance was found when
comparing Brazilian to Ivory Coast YFV samples.
Only four laboratories used two different molecular techniques
for the evaluation, an advantageous approach to exclude false
positives/negatives in routine diagnosis. The four laboratories used
a combination of TaqMan RT-PCR and RT-nested PCR
techniques. Laboratories no. 3 and 16 achieved better scores
when using the TaqMan protocols, whereas laboratories no. 17
and 22 did with the RT-nested PCR ones (Table 1).
Logit analysis was also carried out separately for results obtained
with different RT-PCR techniques. For TaqMan-based real-time
RT-PCR methods 50% performance could be expected when
viral genome concentration was equal to 1.6610
2 GE/sample
(95% CI [0.1–584]) while for the RT nested PCR protocols it was
achieved at 5610
3 GE/sample (95% CI [87–3.7610
4]). 95% of
certainty was achieved with TaqMan real-time RT-PCR at
1.1610
4 GE/sample (95% CI [3610
3–2610
7]), compared to RT
nested PCR at 1610
8 GE/sample (95% CI [2.4610
6–2.8610
15]),
suggesting a better sensitivity of the TaqMan protocols. However,
t-test comparing the TaqMan real-time methods’ performance to
that of RT nested PCR protocols did not reveal any significant
difference in performance of the methods applied. In general, it
seemed that the success of the analysis depended rather on the
performance of the individual laboratories than of the format of
the RT-PCR.
We requested further information on the number of copies of
YFV genome in the samples sent to the participants in order to
estimate the laboratories’ experience in viral load determination.
Only eight results out of 32 (25%) reported quantitative results
(data not shown), although 20 laboratories reported results
obtained by real-time-based procedures which are suitable to
provide quantitative data. Among the reported results, five
provided the quantification estimation as Ct values which give
very limited data to accurately estimate the samples’ viral load in
the absence of calibrated standards.
Another point to consider in view of the results reported is the
use of methods for the generic detection of flavivirus genome. Nine
laboratories reported results using different pan-flavivirus proto-
cols [18–20,23], and five of them correctly differentiated the YFV
samples from other flaviviruses in samples #3 and #11 by
sequencing. This approach (detection plus sequencing) is suitable
for diagnosis purposes as long as a good sensitivity is reached.
Some non-optimal results were due to the presence of false
positives, mainly in sample #3 (only 25% of correct results)
containing the four dengue serotypes and sample #11 containing
other flaviviruses (Table 1). Four laboratories reported false
positive results in samples containing only human plasma, which
indicates the need to improve laboratory procedures since carry-
over contamination must be suspected.
Serological diagnostics results
Most of the serology laboratory results were obtained by using
IIF for the detection of specific YFV antibodies (20 out of 31,
65%), but also ELISA (5 out of 31, 16%), seroneutralization (5 out
of 31, 16%), and haemagglutination (1 set of results, 3%) assays.
Performance varied, depending mainly on the method used and
the subclass of antibodies to be detected but also on the performing
laboratory (Table 2).
Four out of 25 reports (16%) using IIF or ELISA tests did not
include results for IgM antibodies, whereas in the case of IgG
detection only three laboratories (12%) did not report results,
testing only the presence of IgM as marker of infection.
Of the 21 test results for IgM analysis, ten (48%) did not report
the presence of anti-YFV-17D IgM antibodies even in the first
serial dilution of YFV-17D-positive sera. Among them, six results
out of ten (60%) were obtained using a commercial IIF test
(EUROIMMUN), three out of ten (30%) using ‘‘in-house’’ ELISA,
and one out of ten (10%) using a published IIF protocol [25]. In
general, however, in the serial dilutions of samples containing anti-
YFV antibodies against the South-American YFV strain, a good
sensitivity profile was observed. Only seven out of 21 test results
referring to IgM (33%) did not report anti-YF IgM antibodies in
sample #1, the sera sample most diluted. Of these, two out seven
(28.5%) laboratory results were obtained using an ‘‘in-house’’
ELISA test, two out of seven (28.5%) using an ‘‘in-house’’ IIF
method, and three out of seven (42.5%) using a commercial IIF
assay (Table 2).
Two laboratories out of 25 (8%) performing IIF or ELISA
assays reported false-positive IgM detection in sample #2 which
contained antibodies against WNV. However, as many as four
laboratories (16%) reported false-positive results in samples #8
and/or #12 (negative control samples).
Regarding anti-YFV IgG results reported during this EQA, a
better performance was apparently achieved by laboratories using
IIF protocols, as they obtained a higher score in the evaluation
(Table 2).
Two laboratories out of the 22 (9%) sending IgG results
completely failed to detect IgG antibodies. No laboratory reported
the presence of IgG antibodies against YFV (African origin) in
samples #5 and #10. In the serial dilution containing anti-YFV
antibodies against a South-American YFV strain used as sensitivity
control, 86% of the data reported the presence of anti-YFV IgG
antibodies in sample #14, 68% in sample #13, and 45.5% in
sample #1. However, in eight test results (36%) the presence of
anti-YFV IgG (17D) was not detected in the lowest serial dilution
of the YFV-17D-positive sera. Among these, four laboratories out
of eight (50%) used a commercial IIF assay (EUROIMMUN), two
(25%) an ‘‘in-house’’ IIF test, one (12.5%) an IIF assay purchased
from the Bernhard-Nocht-Institut (Hamburg), and one (12.5%)
used two-in house ELISAs. In 13 reports (59%) IgG detection in
YFV-17D samples failed for sample #11, and in 18 reports (82%)
for sample #7 (highest dilution). Unexpectedly, none of the
laboratories using anti-YFV ELISA detected the presence of IgG
properly. Laboratory no. 19 reported the detection of IgG in
samples #1 and #7 but not in previous dilutions of the same
samples.
False IgG positives were reported in six laboratory results, three
of them in samples #2 and #9 containing antibodies against other
flaviviruses, and another three in sample #12, a negative control
serum. The fact that other laboratories using the same commercial
assays did not report these false positives results, suggests a
problem in the operational procedures rather than a non-specific
cross-reactivity of the assays.
In general, no difference in performance was found for IIF and
ELISA assays or for the usage of commercial versus ‘‘in-house’’
assays (data not shown), nor was a difference found in the
Yellow Fever Diagnosis External Quality Assessment
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e36291detection accuracy for IgM and IgG anti-YFV antibodies
(McNemar’s test).
The data obtained by seroneutralization assays do not allow to
distinguish among IgM and IgG antibodies since the assay
determines the presence of total neutralizing antibodies. Seroneu-
tralization assays are expected to be the most specific ones in
flavivirus serological diagnostics. In this study they showed a good
performance with high scores (Table 2). Indeed, even in the low-
titre sample #5 (IgM2/IgG+) laboratories nos. 15 and 30
reported a correct positive result. However, the presence of
false-positive results for samples #8 and #12 raises the question
whether these results are due to a higher sensitivity or a strong
background in the test. Control samples for the cytotoxicity effect
and controls for virus infectivity must be included in each assay to
be able to interpret the results correctly.
The haemagglutination assay which was only used by labora-
tory no. 20 showed a very low sensitivity, with only sample #14
reported as positive (Table 2).
Discussion
This is the first international EQA on YF diagnostics. The
increasing importance of this disease in Africa and the Americas,
and the risk of expansion to other areas, makes it necessary to
assure that the methods used for YFV diagnostics and surveillance
are working properly where they are already implemented.
Among the participating laboratories 20 out of 36 (56%)
reported both serological and molecular results, indicating that
they routinely include both approaches in their diagnostic
algorithm. However, 22% (eight out of 36) of the participants
applied only molecular or serological techniques, respectively,
leaving room for the presence of false-negative results depending
not only on the accuracy of the methods but also on the time
period between the onset of disease and the diagnosis. We
recommend combining both molecular and serological methods to
provide the best accuracy in the diagnosis of wild-type YFV
infections and YFVAE, an approach which increases the diagnosis
window while minimizing the risk of false-negatives results.
Likewise we also recommend the use of paired samples, when
possible, to validate the results obtained in acute samples by
confirming the presence/absence of seroconversion. This strategy
is useful for the detection of false positives due to cross-
contaminations in the case of molecular diagnosis or false isolated
IgM positives in the case of serological diagnosis.
Regarding molecular diagnosis EQA, the participants using
TaqMan real-time RT-PCR-based techniques overall showed a
better performance with a higher sensitivity than other assays.
However, the major limitation for the implementation of these
assays is the costs of both thermocyclers and reagents which
hamper a generalized application in the field.
One of the main weaknesses observed during this EQA was the
inability of some protocols to detect the YFV genome of wild-type
strains. Five out of eight laboratories which failed to recognize all
wild-type YFV strains used the TaqMan real-time RT-PCR
described by Bae et al. [21], two out of eight used ‘‘in-house’’
methods, and one applied the method previously described by
Brown et al. [22] who already pointed out that false negatives
might occur when using this protocol. One laboratory used a
TaqMan real-time RT-PCR previously described exclusively for
the detection of YFV vaccine strain 17D [16], which would
explain the results obtained. However, the methods mentioned
above showed a very good sensitivity profile against YFV-17D,
making them useful tools to identify viral genome in suspected
YFVAE or research, but obviously not to identify suspected wild-
type cases. The presence of mismatches between the oligonucle-
otide and the viral target sequences might explain the failure in
genome amplification. This denotes the need to adapt and up-date
regularly oligonucleotide sequences in use in diagnosis laboratories
to detect the presence of mutations in the circulating strains which
may compromise the ability of the assay to amplify and/or detect
the targeted sequence leading to false negative results. However,
among those laboratories which failed to detect only one of the
wild-type strains (South American [Brazil] or West African
[IvoryC1999]), two laboratories reported the use of the TaqMan
real-time RT-PCR described by Drosten et al. [20], one
laboratory used the RT-nested PCR by Kuno [15], and one
laboratory used an ‘‘in-house’’ protocol. Other participants
applied the method published by Drosten et al., with optimal
detection of all YFV strains. Therefore, it seems in these cases that
failure in detecting some strains might more likely be due to the
specific performance of the laboratories rather than to the
techniques themselves, suggesting the need to revise the running
protocols of these laboratories to improve the quality of their
results.
One laboratory completely failed in the detection of all positive
samples. It can not be excluded that the gamma irradiation of the
samples for inactivation could have resulted in nicked RNA that
would affect those methods amplifying fragments of around
600 bp [26] as it is the case of the method used by this laboratory
[17]. However, other laboratories reported good results with
bigger amplification targets so probably other factors might have
influenced the performance of this laboratory.
Similarly, the presence of false-positive results in flavivirus
RNA-free samples also denoted the need to optimize laboratory
practices in order to avoid the occurrence of cross-contamination.
It is remarkable that for the sample containing genome of the
four dengue serotypes (sample #3) only 25% of the results were
correct. In the meantime the possibility of the presence of
contaminant traces of YFV genome due to the processing and
preparation of the samples has been excluded, and these results
could indicate some degree of non-specificity in the techniques. As
dengue is a common differential diagnosis for YFV, such
specificity issues should be taken into consideration while
interpreting dengue or YFV diagnostic testing results.
Twenty-eight percent of the tests reported used a generic
flavivirus assay for the detection of YFV RNA, and 55.5% of these
correctly differentiated the presence of YFV genome from that of
other flaviviruses by consecutive sequencing. This approach might
be advantageous for diagnostic purposes in laboratories which
need to cover the possibility of infections with different flaviviruses
without holding available a specific protocol for each of them.
However, we must point out that the use of these generic methods
must always be accompanied by sequence identification, mainly in
endemic areas where usually more than one of the flaviviruses
circulates.
As in previous EQA studies, data regarding viral load were
scarce even though the use of real-time techniques was prominent
[12].
Regarding the serological results of this EQA, one of the main
observations was the fact that 16% of the participating laboratories
do not routinely include the analysis of specific anti-YFV IgM in
their diagnostic algorithms. It is well known that for the serological
diagnosis of an acute YFV infection it is preferable to test for the
presence of IgM which appears for a short period of time soon
after the infection, confirming a recent contact with the virus. The
presence of IgG does not provide a good proof of recent YFV
infection and requires the analysis of a second sample to confirm a
rise in the antibody titres. In general, the sole detection of IgG
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vaccination, or with another flavivirus as serological cross-
reactivity is more pronounced for IgG detection than for IgM,
as suggested by this EQA and previous reports [27–29]. It is
important to note that in general the existence of this cross-
reactivity is the major weakness of the serological diagnosis, not
only for YFV but for all flaviviruses. Seroneutralization assays are
considered the ‘‘gold standard’’ for specific identification of a
positive immune response. However, some degree of non-
specificity can not be excluded and such a technique requires
the use of well-characterized controls. Additionally, seroneutrali-
zation assays can perform poorly in samples with multiple/
subsequent infections unless multiple samples are available. Also
the material, the expertise, and the time required to perform a
seroneutralization assay do not make it a proper choice for early
diagnosis.
Fortunately, from the results of this EQA it has become obvious
that false positives due to cross-reactivity are not the main
limitation of the serological techniques used by the participating
laboratories, and that most of the specificity difficulties could be
solved by proper standardization of the protocols and the use of
adequate controls during the assays.
One of the main issues that deserve more attention is the
apparent lack of sensitivity regarding anti-YFV-17D IgM detec-
tion in 48% of the results reported, while a good sensitivity profile
was observed in wild-type infection sera. This should be taken into
account when assessing the protection provided by the YFV
vaccines by determining IgM levels.
In the case of IgG detection, apparently the quality of the results
depends mostly on the performing laboratories since their results
differ even when using the same technique. The lack of detection
of IgG in sample #5 has no major impact on the conclusions of
this EQA since the samples from West African wild type infection
contained the lower titre of antibodies compared to the others, and
required very sensitive techniques for detection, which could only
be achieved by seroneutralization assays in this EQA. Similarly,
the presence of false-positive results in those laboratories with
other correct results makes it unclear whether a low threshold of
detection could imply a higher risk for false-positive results to
occur.
We conclude that the main differences in the molecular
diagnosis results might be more related to the handling of assays
and specimens, pointing out the importance of regularly revising
and improving the operational protocols. The different profiles of
strain detection obtained with each protocol must be taken into
account by the laboratories which must select those protocols most
suitable for their particular diagnosis purpose (wild-type infections
vs. YFVAE).
In general, commercial serological assays showed a very good
sensitivity profile in this study for both IgM and IgG detection of
wild-type origin, but not for antibody detection against the vaccine
strain YFV-17D. Commercial serological assays used for diagnos-
tic purposes show a better specificity when compared to ‘‘in-
house’’ ones. However, their use raises some concern when
evaluating the immune response elicited after vaccination.
No difference in the sensitivity detection of IgM and IgG anti-
YF antibodies has been found in this EQA, in contrast with the
results observed in previous EQA studies on other arboviral
infections [11,30,31]. However, the different titres of IgM and IgG
in the samples included in this EQA make this comparison quite
general.
The low participation of endemic countries in this EQA, even
though widely announced, points out the need to encourage more
laboratories to implement YFV diagnosis techniques and to
participate routinely in quality assurance programmes.
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